T2 Biosystems

T2 Biosystems, Inc. engages in the development of a proprietary technology platform. It offers the T2 Magnetic Resonance technology, which enables detection of pathogens, biomarkers, and other abnormalities in a range of unpurified patient sample types. The firm's products include the T2Dx Instrument, the T2Candida Panel, the T2Bacteria Panel, the T2Resistance Panel, and the T2SARS-CoV-2 Panel. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

T2 Biosystems reports revenue growth, eyes FDA breakthroughs for expansion

T2 Biosystems demonstrated strong revenue growth and operational improvements in Q3 2024, driven by sepsis test panel sales and strategic partnerships.
While facing financial challenges and regulatory complexities, the company's focus on innovation and market expansion presents significant opportunities for future growth.
Overall, T2 Biosystems remains optimistic about its growth prospects, supported by advancements in its product pipeline and collaborations to combat healthcare challenges.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

T2 Biosystems, Inc. is a vitro diagnostics company, which engages in the development of detection of sepsis-causing pathogens. It offers T2Dx instrument, T2Bacteria, T2Candida, T2Biothreat panels, and T2MR technology. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.

Enters Exclusive Distribution Agreement to Expand Sales in Israel Enters Exclusive Distribution Agreement to Expand Sales in Israel

T2 Biosystems Announces Preliminary Fourth Quarter 2019 Financial Results

LEXINGTON, Mass., Jan.  09, 2020  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative diagnostic products for critical unmet needs in healthcare, today announced that its Board of Directors has appointed diagnostics industry veteran John Sperzel as President and Chief Executive Officer (CEO), effective immediately. Mr. Sperzel, who will also join the Board of Directors, succeeds John McDonough, who will continue with his Board leadership role serving as non-Executive Chairman. 

T2 Biosystems Appoints Industry Veteran John Sperzel as Chief Executive Officer

The T2Resistance Panel is the only direct-from-blood diagnostic designed to detect genetic markers associated with antibiotic-resistant bloodstream infections The T2Resistance Panel is the only direct-from-blood diagnostic designed to detect genetic markers associated with antibiotic-resistant bloodstream infections

T2 Biosystems Announces Granting of CE-Mark for T2Resistance™ Panel

T2 Biosystems, Inc. (TTOO) CEO John McDonough on Q3 2019 Results - Earnings Call Transcript

T2 Biosystems (TTOO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate T2 Biosystems (TTOO) to Report a Decline in Earnings: What to Look Out for

Earnings Preview: T2 Biosystems (TTOO) Q3 Earnings Expected to Decline

T2 Biosystems, Inc. (TTOO) CEO John McDonough on Q2 2019 Results - Earnings Call Transcript

T2 Biosystems announced it has feasibility data to potentially make a panel that will cover over >99% of blood infections by detecting over 250 pathogen species.

T2 Biosystems Announced The Holy Grail For Blood-Borne Pathogen Detection But No One Noticed (Yet)

T2 has spine-tingling potential, however, it is struggling to prove itself.

T2: A Catch With A Catch

T2 Biosystems is a company that might revolutionize the way blood cultures are done.

T2 Biosystems: Why The Bears Are Wrong

T2 Biosystems has been bad news for investors.

T2: Navigating The Danger Zone

T2 Biosystems got a boost in trading on Friday after delivering better than expected Q1 results after the bell on Thursday.

T2 Biosystems: Turning Point Achieved?

T2 Biosystems, Inc. (TTOO) CEO John McDonough on Q1 2019 Results - Earnings Call Transcript

T2 Biosystems (TTOO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

T2 Biosystems (TTOO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

News for T2 Biosystems Stock (TTOO)